How do you approach second-line therapy for patients with PD-L1 positive metastatic TNBC, after progression on sacituzumab govitecan + pembrolizumab?

Tolaney, et al., PMID: 41564397

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

What are your top takeaways in Breast Cancer from ESMO 2025?

How would you approach systemic treatment of oligometastatic recurrence following surgical removal of the single area of metastasis in a patient with ER+ (20-30%), PR-negative, HER2-negative breast cancer?

What are your top takeaways in Radiation Oncology from SABCS 2025?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
TrialMatch
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.